ESLA

Estrella Immunopharma, Inc. Common Stock

1.44

USD

ESLA Earnings Reports

Positive Surprise Ratio

ESLA beat 2 of 3 last estimates.

67%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q1 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Estrella Immunopharma, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, ESLA reported earnings of -0.13 USD per share (EPS) for Q1 26, beating the estimate of -0.19 USD, resulting in a 32.92% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +4.76% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Amgen Inc

Report Date

Feb 03, 2026 For Q4 25

Estimate

$4.82

Actual

$5.29

Surprise

+9.56%

Bristol-Myers Squibb Co.

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.12

Actual

$1.26

Surprise

+11.88%

GSK plc - ADR

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.23

Actual

$0.49

Surprise

+111.36%

Biogen Inc. Common Stock

Report Date

Feb 06, 2026 For Q4 25

Estimate

$1.62

Actual

$1.99

Surprise

+22.39%

Illumina Inc

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.24

Actual

$1.35

Surprise

+8.01%

QIAGEN N.V.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.64

Actual

$0.62

Surprise

-3.32%

Arrowhead Research Corporation

Report Date

Feb 05, 2026 For Q1 26

Estimate

$0.25

Actual

$0.22

Surprise

-14.76%

Bio-Techne Corp.

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.44

Actual

$0.46

Surprise

+3.95%

Immunovant, Inc. Common Stock

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.72

Actual

-$0.61

Surprise

+16.27%

Adaptive Biotechnologies Corporation Common Stock

Report Date

Feb 05, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.09

Surprise

+51.33%

FAQ

What were Estrella Immunopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?

For Q1 2026, Estrella Immunopharma, Inc. Common Stock reported EPS of -$0.13, beating estimates by 32.92%, and revenue of --, -- -- expectations.

How did the market react to Estrella Immunopharma, Inc. Common Stock's Q1 2026 earnings?

The stock price moved up 4.76%, changed from $2.10 before the earnings release to $2.20 the day after.

When is Estrella Immunopharma, Inc. Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Estrella Immunopharma, Inc. Common Stock's next earnings report?

Based on -- analysts, Estrella Immunopharma, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.